SPDL1 and non-small cell lung carcinoma: In a similar fashion, Zizzari et al. observed that low levels of sPDL-1, sPDL-2, sTim3, sCD137, and sBTLA were correlated with a longer response to anti-PD1 treatment in NSCLC patients [30].